Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Enterprise Value (2016 - 2025)

Arrowhead Pharmaceuticals' Enterprise Value history spans 16 years, with the latest figure at -$922.3 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 67.87% year-over-year to -$922.3 million; the TTM value through Dec 2025 reached -$922.3 million, down 67.87%, while the annual FY2025 figure was -$882.0 million, 30.6% down from the prior year.
  • Enterprise Value reached -$922.3 million in Q4 2025 per ARWR's latest filing, down from -$882.0 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$126.0 million in Q4 2021 to a low of -$1.1 billion in Q1 2025.
  • Average Enterprise Value over 5 years is -$511.5 million, with a median of -$448.6 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: tumbled 456.52% in 2021, then surged 57.1% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$126.0 million in 2021, then tumbled by 282.92% to -$482.5 million in 2022, then soared by 57.1% to -$207.0 million in 2023, then crashed by 165.42% to -$549.4 million in 2024, then tumbled by 67.87% to -$922.3 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Enterprise Value are -$922.3 million (Q4 2025), -$882.0 million (Q3 2025), and -$902.9 million (Q2 2025).